The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Newcastle just need a draw or a loss by one goal against Arsenal in today's second leg of the Carabao Cup semi-final at St.

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

New polling data indicates nearly 80% of working-age Canadians worry they would struggle to save for retirement if faced with a cancer diagnosis due to substantial out-of-pocket ...